(Q27853337)

English

Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

scientific article

In more languages

Statements

scholarly article

1 reference

13 November 2016

Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial (English)

1 reference

13 November 2016

phase III clinical trial

0 references

0 references

multicenter clinical trial

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

15

0 references

Gunter von Minckwitz

10

0 references

1

0 references

16

object named as

Marc Buyse

0 references

Suzette Delaloge

2

object named as

Suzette Delaloge

0 references

11

object named as

Bent Ejlertsen

0 references

Norikazu Masuda

20

object named as

Norikazu Masuda

0 references

5

object named as

Hiroji Iwata

0 references

4

object named as

Beverly Moy

0 references

author name string

Frankie A Holmes

3

0 references

Vernon J Harvey

6

0 references

Nicholas J Robert

7

0 references

Tajana Silovski

8

0 references

Erhan Gokmen

9

0 references

Stephen K L Chia

12

0 references

Janine Mansi

13

0 references

Carlos H Barrios

14

0 references

Ira Gore

17

0 references

John Smith

18

0 references

Graydon Harker

19

0 references

Katarina Petrakova

21

0 references

Angel Guerrero Zotano

22

0 references

Nicholas Iannotti

23

0 references

Gladys Rodriguez

24

0 references

Pierfrancesco Tassone

25

0 references

Alvin Wong

26

0 references

Richard Bryce

27

0 references

publication date

March 2016

0 references

Lancet Oncology Commission

0 references

17

0 references

3

0 references

367-77

0 references

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900551-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900551-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900551-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Adjuvant trastuzumab in HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900551-3

7 January 2021

based on heuristic

inferred from DOI database lookup

2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900551-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900551-3

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900551-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900551-3

7 January 2021

based on heuristic

inferred from DOI database lookup

HER2 therapy: molecular mechanisms of trastuzumab resistance.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900551-3

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900551-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900551-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Mechanisms of disease: Oncogene addiction--a rationale for molecular targeting in cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900551-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers--role of estrogen receptor and HER2 reactivation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900551-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900551-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900551-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Oncogene addiction

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900551-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Analysis of data from multiclinic trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900551-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900551-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parall

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900551-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900551-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900551-3

7 January 2021

based on heuristic

inferred from DOI database lookup

A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900551-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Therapeutic implications of estrogen receptor signaling in HER2-positive breast cancers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900551-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900551-3

7 January 2021

based on heuristic

inferred from DOI database lookup

CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900551-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer: The NEfERT-T Randomized Clinical Trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900551-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Guidance on the management of diarrhoea during cancer chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900551-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety and efficacy of neratinib in combination with weekly paclitaxel and trastuzumab in women with metastatic HER2‑positive breast cancer: an NSABP Foundation Research Program phase I study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900551-3

7 January 2021

based on heuristic

inferred from DOI database lookup

A combination of distribution- and anchor-based approaches determined minimally important differences (MIDs) for four endpoints in a breast cancer scale

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900551-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900551-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900551-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900551-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Letrozole in the extended adjuvant treatment of postmenopausal women with history of early-stage breast cancer who have completed 5 years of adjuvant tamoxifen

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900551-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(15)00551-3

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q27853337&oldid=1966902200"